Absci Corporation (ABSI) and AstraZeneca have joined forces in a groundbreaking collaboration to utilise generative AI for the discovery of antibodies targeting cancer. Absci, known for its innovative AI technology, will employ its AI Engine to design a therapeutic antibody focused on a specific oncology target.
AstraZeneca's commitment includes upfront support, research and development funding, milestone payments, and future royalties, showcasing confidence in Absci's approach. The collaboration aims to expedite the discovery of a potential cancer treatment by combining Absci's Integrated Drug Creation™ platform, featuring generative AI and wet-lab technologies, with AstraZeneca's extensive oncology expertise.
Absci's platform integrates generative AI with state-of-the-art wet-lab techniques, creating a powerful synergy. The platform generates proprietary data by analysing millions of protein-protein interactions, training AI models that are validated in the real world, and establishing a continuous feedback loop. This accelerated drug discovery process, completed within approximately six weeks, enhances the success rate of developing new biologic drugs. The platform's ability to optimise multiple drug features simultaneously addresses previously challenging targets like GPCRs and ion channels.
The collaboration between Absci and AstraZeneca signals a promising advancement in cancer treatment innovation. By harnessing the capabilities of AI, this partnership has the potential to significantly speed up drug discovery, offering new possibilities for cancer patients globally and addressing previously considered "undruggable" targets.
Click here to read the original news story.